Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that topical minoxidil 5% foam may effectively promote hair growth in congenital alopecia and hypotrichosis linked to desmoplakin mutations, as demonstrated by significant hair growth in an 8-year-old boy.

This study found that a once-daily 5% minoxidil topical foam is as effective as a twice-daily 2% minoxidil topical solution for hair growth in women with androgenetic alopecia, with fewer side effects and greater styling convenience.

This case report describes a 27-year-old woman who experienced facial swelling due to allergic contact dermatitis from using minoxidil 5% foam.

This study found that the "pink tax" persists in topical minoxidil products, with foams marketed to women costing about 20% more than those for men, despite identical ingredients and an overall price increase since 2017.

This study found that hair follicles are a significant and efficient pathway for the absorption of topical minoxidil foam in humans, with faster blood detection when follicles are open.

In this study, once-daily 5% minoxidil foam and twice-daily 2% minoxidil solution both promoted hair regrowth in women with female pattern hair loss, but noninferiority of the foam was not established.

This study reviewed the evidence on minoxidil's effectiveness for androgenetic alopecia, finding that 5% topical minoxidil is the most effective monotherapy for men, while 2% is similarly effective for women. Genetic markers can predict response, and new formulations like foam and gel improve tolerability.

This case report details a 2-year-old boy who developed generalized hypertrichosis after using 5% minoxidil foam for alopecia areata, highlighting the importance of caution and proper administration instructions for young children.

This case study found that a 9-year-old girl with trichorhinophalangeal syndrome type 1 experienced significant improvements in hair density and length after 4 months of topical minoxidil treatment, suggesting its therapeutic potential for this condition.

Once-daily 5% minoxidil foam increases hair regrowth and density in women with hair loss, but not as effectively as twice-daily 2% minoxidil solution, though it's safer and more convenient.

The document concludes that various dermatological treatments and drugs can cause skin reactions and side effects.

This systematic review and meta-analysis found that low-dose minoxidil treatment effectively enhances facial hair development with relatively minimal side effects, which can be beneficial in primary care settings.

A woman developed a scalp condition from using minoxidil, which improved with a different treatment but left scarring.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This pilot study found that a novel regimen including NuH Hair led to significant hair growth in male patients with androgenic alopecia, regardless of atopy status, with quicker results when additional treatment components were used.

This case report describes a unique presentation of frontal fibrosing alopecia characterized by a hair loss pattern that resembles the Greek letter upsilon, supported by trichoscopic and histological findings.

Scalp micro-wounding helps promote hair growth in female pattern hair loss.

Over 40% of postmenopausal women experience hair loss, with treatments aiming to stop further loss and possibly thicken hair.

This review discusses current medical therapies available for treating hair loss and emphasizes the importance of understanding these options, but it presents no new results.

Certain hairstyles can cause scalp diseases, smoking is linked to hair loss, 5% minoxidil foam is effective for hair loss treatment, and various factors influence wound healing and hair growth.

Transfollicular drug delivery can improve medication absorption through hair follicles.

This source provides no abstract, offering no results or conclusions on a case involving a 14-year-old boy with abrupt-onset hair changes presented in a photo quiz format in Pediatric Dermatology.

This study found that topical minoxidil 5% foam was effective in promoting hair growth in both the frontal and vertex scalp for men with androgenetic alopecia.

This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.

This review discusses the use of topical minoxidil for various types of alopecia and reports mixed evidence on its efficacy, with stronger support noted for conditions like eyebrow hypotrichosis and chemotherapy-induced alopecia.

This study found that 14 days of low-dose aspirin reduced the predicted response to topical minoxidil in androgenetic alopecia patients from 50% to 27%, suggesting aspirin may inhibit minoxidil efficacy.

This report describes nine women who were allergic to topical minoxidil but successfully tolerated low-dose oral minoxidil without significant adverse effects, suggesting it may be a viable alternative for those with similar allergies.

This case report describes a non-arteritic anterior ischemic optic neuropathy that resolved after discontinuing topical 5% minoxidil treatment.

This study suggests that the novel "After Minoxidil" spray improved styling ease and reduced greasiness in patients using topical minoxidil, which may enhance compliance and treatment efficacy.

Female-marketed minoxidil foam is more expensive than male-marketed, but generic and bulk options can reduce this gap.